DK0723439T3 - Kombination af progesteronantagonister og antiøstrogener med partiel agonistisk virkning til hormonsubstitutionsterapi til - Google Patents

Kombination af progesteronantagonister og antiøstrogener med partiel agonistisk virkning til hormonsubstitutionsterapi til

Info

Publication number
DK0723439T3
DK0723439T3 DK94929553T DK94929553T DK0723439T3 DK 0723439 T3 DK0723439 T3 DK 0723439T3 DK 94929553 T DK94929553 T DK 94929553T DK 94929553 T DK94929553 T DK 94929553T DK 0723439 T3 DK0723439 T3 DK 0723439T3
Authority
DK
Denmark
Prior art keywords
pct
action
antiestrogen
progesterone
antiestrogens
Prior art date
Application number
DK94929553T
Other languages
Danish (da)
English (en)
Inventor
Kristof Chwalisz
Klaus Stoeckemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK0723439T3 publication Critical patent/DK0723439T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK94929553T 1993-10-17 1994-10-17 Kombination af progesteronantagonister og antiøstrogener med partiel agonistisk virkning til hormonsubstitutionsterapi til DK0723439T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4335876A DE4335876A1 (de) 1993-10-17 1993-10-17 Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
PCT/EP1994/003408 WO1995011013A2 (de) 1993-10-17 1994-10-17 Kombination von progesteronantagonisten und antiöstrogenen mit partialer agonistischer wirkung für die hormonsubstitutions-therapie für peri- und postmenopausale frauen

Publications (1)

Publication Number Publication Date
DK0723439T3 true DK0723439T3 (da) 2000-10-30

Family

ID=6500646

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94929553T DK0723439T3 (da) 1993-10-17 1994-10-17 Kombination af progesteronantagonister og antiøstrogener med partiel agonistisk virkning til hormonsubstitutionsterapi til

Country Status (19)

Country Link
US (1) US5719136A (no)
EP (1) EP0723439B1 (no)
JP (1) JPH09503774A (no)
KR (1) KR100348116B1 (no)
CN (1) CN1128613C (no)
AT (1) ATE196251T1 (no)
AU (1) AU691839B2 (no)
CA (1) CA2174327C (no)
CZ (1) CZ285690B6 (no)
DE (2) DE4335876A1 (no)
DK (1) DK0723439T3 (no)
ES (1) ES2150503T3 (no)
GR (1) GR3035054T3 (no)
HU (1) HUT74430A (no)
NO (1) NO308584B1 (no)
NZ (1) NZ274510A (no)
PT (1) PT723439E (no)
SK (1) SK281312B6 (no)
WO (1) WO1995011013A2 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE214269T1 (de) * 1997-06-27 2002-03-15 Akzo Nobel Nv Oral anzuwendende flüssige arzneilösung
CN1309637A (zh) * 1998-05-15 2001-08-22 美国家用产品公司 包含2－苯基－吲哚化合物和雌激素制剂的组合物
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
US6339098B1 (en) * 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN1662234A (zh) * 2002-06-25 2005-08-31 惠氏公司 硫代－羟吲哚衍生物在治疗与激素有关的病症中的用途
EP1515680A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp USE OF THIO-OXINDOLE DERIVATIVES IN THE TREATMENT OF SKIN DISORDERS
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
WO2004112724A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
US7247625B2 (en) * 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
US7323455B2 (en) * 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US7319152B2 (en) * 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
US20070066628A1 (en) * 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US7414142B2 (en) * 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
MX2008014825A (es) * 2006-05-22 2008-12-01 Hormos Medical Ltd Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US20080045560A1 (en) * 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
US7649007B2 (en) * 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
US7618989B2 (en) * 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
WO2008021309A1 (en) * 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
EP2821385B1 (en) * 2007-02-14 2016-07-27 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
CL2008000662A1 (es) * 2007-03-09 2008-04-25 Wyeth Corp Forma cristalina de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il) tiazo-4-il) benzonitrilo; metodo para la preparacion de dicho compuesto; composicion farmaceutica que comprende a dicho compuesto; kit farmaceutico que comprende a dicho compuesto; y su uso
US20080306131A1 (en) * 2007-06-05 2008-12-11 Wyeth Progesterone receptor modulator and uses thereof
EP2909164A1 (en) 2012-10-19 2015-08-26 Fermion Oy A process for the preparation of ospemifene

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
KR960704535A (ko) 1996-10-09
NO961502L (no) 1996-06-14
CZ285690B6 (cs) 1999-10-13
NO961502D0 (no) 1996-04-16
ES2150503T3 (es) 2000-12-01
NO308584B1 (no) 2000-10-02
WO1995011013A3 (de) 1995-06-29
WO1995011013A2 (de) 1995-04-27
US5719136A (en) 1998-02-17
CN1128613C (zh) 2003-11-26
SK281312B6 (sk) 2001-02-12
PT723439E (pt) 2001-01-31
SK48496A3 (en) 1997-01-08
EP0723439B1 (de) 2000-09-13
DE4335876A1 (de) 1995-04-20
KR100348116B1 (ko) 2002-11-25
DE59409522D1 (de) 2000-10-19
CA2174327C (en) 2007-05-22
CZ111196A3 (en) 1996-08-14
AU7856494A (en) 1995-05-08
AU691839B2 (en) 1998-05-28
NZ274510A (en) 2001-03-30
JPH09503774A (ja) 1997-04-15
HU9600992D0 (en) 1996-06-28
HUT74430A (en) 1996-12-30
ATE196251T1 (de) 2000-09-15
CA2174327A1 (en) 1995-04-27
GR3035054T3 (en) 2001-03-30
EP0723439A1 (de) 1996-07-31
CN1135176A (zh) 1996-11-06

Similar Documents

Publication Publication Date Title
DK0723439T3 (da) Kombination af progesteronantagonister og antiøstrogener med partiel agonistisk virkning til hormonsubstitutionsterapi til
DE69527706T2 (de) Zusammensetzungen, die einen die mastzellendgranulation blockierenden h-1 rezeptorantagonisten als wirkstoff enthalten, für die behandlung von endogenen, schmerzhaften gastrointestinalen beschwerden nichtentzündlichen, nichtulzerativen ursprungs
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
AR019847A1 (es) COMPOSICIoN SINÉRGICA PARA EL CONTROL DE PESTES ANIMALES, USO DE DICHA COMPOSICIoN PARA EL CONTROL DE LAS PESTES ANIMALES Y PROCEDIMIENTO PARA PREPARAR DICHAS COMPOSICIONES.
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
NO20054249L (no) Anvendelse av komposisjon for fremstilling av et farmasoytisk preparat for forhindring eller behandling av kloe hos en pasient
MY117251A (en) Use of central cannabinoid receptor antagonists for the preparation of drugs
AR011114A1 (es) COMPOSICIoN FARMACÉUTICA LIBRE DE LACTOSA EN FORMA GRANULADA O EN MEZCLA PARA EL TRATAMIENTO DE DESoRDENES INDUCIDOS POR HISTAMINA.
FI963083A (fi) Normotensiivisen glaukooman hoito angiotensiini-II-antagonisteilla
Cohen et al. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder
ATE171873T1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
SE9903995D0 (sv) New combination
KR100253111B1 (en) Pharmaceutical compositions of alkylsulphonamides 5ht1 agonists for rectal administration
IS2702B (is) Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun
ES2136615T3 (es) Nuevos inhibidores de glucohidrolasa utiles como agentes antidiabeticos, antiviricos y antimetastasicos.
UA85190C2 (en) PROCESS FOR THE SYNTHESIS OF PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS AND THE MIXTURE OF ISOMERS, AND USE OF THOSE ISOMERS
DK0755184T3 (da) Nye pesticidblandinger og fremgangsmåde til fremstilling deraf
GR3024854T3 (en) Drugs for preventing the development of tolerance during treatment with benzodiazepine-receptor-binding substances.
DK0701556T3 (da) N-((1-(4-(4-fluorphenoxy)butyl)-4-piperidinyl)N-methylamino)-2-benzo-thiazothiazololer som klasse III-antiarrytmiske midler